MedTrace Logo

Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule

NCT00572000 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2007-12-12

No results posted yet for this study

Summary

The purpose of this study is to assess the occurrence of serious adverse events (SAEs) as well as evaluate the occurrence of solicited local and solicited general symptoms and the occurrence of medically significant conditions reported throughout the study period.

Conditions

  • Human Papillomavirus (HPV) Vaccine

Interventions

BIOLOGICAL

HPV-16/18 L1 VLP AS04 vaccine

Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month

Sponsors & Collaborators

  • National Institute for Control of Vaccine and Biologicals

    lead OTHER_GOV

Principal Investigators

  • Son Hoa Hoang, Medicine Doctor · National Institute for Control of Vaccine and Biologicals

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-11-30
Completion
2008-06-30

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00572000 on ClinicalTrials.gov